Bucillamine - Revive Therapeutics

Drug Profile

Bucillamine - Revive Therapeutics

Alternative Names: REV-002; REV-004; REV-005

Latest Information Update: 07 Jul 2016

Price : $50

At a glance

  • Originator Revive Therapeutics
  • Class Cysteines; Disease-modifying antirheumatics; Nonsteroidal anti-inflammatories; Purines; Small molecules; Sulfhydryl compounds; Sulfur amino acids
  • Mechanism of Action Chelating agents; Immunomodulators; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystinuria
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Gout
  • Phase I Hepatolenticular degeneration
  • Research Cystinuria

Most Recent Events

  • 06 Jul 2016 The US FDA accepts IND application for bucillamine in Cystinuria
  • 23 May 2016 Bucillamine - Revive Therapeutics is available for licensing as of 23 May 2016. http://www.revivethera.com/company___revive_therapeutics_ltd_en_302cms.htm
  • 10 May 2016 Revive Therapeutics plans to file an IND application with the US FDA for Cystinuria in first quarter of 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top